Amanote Research
Register
Sign In
A Budget Impact Model for the Introduction of Bevacizumab for the Treatment of Newly Diagnosed Glioblastoma Multiforme in the UK
Value in Health
- United Kingdom
doi 10.1016/j.jval.2014.03.440
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
May 1, 2014
Authors
A.M Scola
K. Lock
C.A. Ngoh
Publisher
Elsevier BV
Related search
Cytotoxic Chemotherapeutic Management of Newly Diagnosed Glioblastoma Multiforme
Journal of Neuro-Oncology
Cancer Research
Oncology
Neurology
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Using Temozolomide in Newly Diagnosed Glioblastoma Multiforme – A Single-Centre Experience
Wspolczesna Onkologia
Oncology
Radiology
Nuclear Medicine
Imaging
Update and Developments in the Treatment of Glioblastoma Multiforme &Ndash; Focus on Bevacizumab
Pharmacogenomics and Personalized Medicine
Molecular Medicine
Pharmacology
Controversies in the Treatment of Elderly Patients With Newly Diagnosed Glioblastoma
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Single Dose Bevacizumab as Treatment for Symptomatic, Corticosteroid-Refractory Pseudoprogression After Chemoradiation Therapy for Newly Diagnosed Glioblastoma: A Case Report
Integrative Cancer Science and Therapeutics
Efficacy and Safety of Bevacizumab for the Treatment of Glioblastoma
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
The Use of Anti-Gitr Antibody Treatment in a Murine Model of Glioblastoma Multiforme
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Plasma YKL-40 as a Biomarker for Bevacizumab Efficacy in Patients With Newly Diagnosed Glioblastoma in the Phase 3 Randomized AVAglio Trial
Oncotarget
Oncology
